{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Relmada Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"RLMD"},"Address":{"label":"Address","value":"2222 PONCE DE LEON BOULEVARD,FLOOR 3, CORAL GABLES, Florida, 33134, United States"},"Phone":{"label":"Phone","value":"+1 786 629-1376"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications."},"CompanyUrl":{"label":"Company Url","value":"https://www.relmada.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Paolo Manfredi","title":"Chief Scientific Officer"},{"name":"Sergio Traversa","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}